Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phentermine + cyanocobalamin
- Development stage
- Phase 1
- Lead developer
- Michael Lang
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
This is an investigational combination therapy consisting of oral phentermine and intramuscular vitamin B12 (cyanocobalamin) injections. Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine in the hypothalamus, primarily through its action on the norepinephrine transporter and trace amine-associated receptor 1. Vitamin B12 is included as a weekly injection to potentially enhance metabolic function and weight loss effects, although its specific contribution to the efficacy of this combination is the subject of clinical investigation. The therapy was evaluated in a pilot randomized controlled trial led by Dr. Michael Lang at East Carolina University (ECU Physicians) for the treatment of obesity, comparing the combination's weight loss outcomes against phentermine monotherapy.
- Other names
- Phentermine and B12Phentermine and Vitamin B12Phentermine plus B12
02
Targets
MAOB (Monoamine oxidase B)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)TAAR1 (Trace amine-associated receptor 1)
Beyond the preview
Go deeper on phentermine + cyanocobalamin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phentermine + cyanocobalamin.